CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?
Abstract Chimeric antigen receptor T-cell (CAR-T) therapy has been prosperous in the treatment of patients with various types of relapsed/refractory (R/R) B-cell malignancies including diffuse large B-cell lymphoma (DLBCL), B-cell acute lymphoblastic leukemia (B-ALL), follicular lymphoma (FL), mantl...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-10-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13287-021-02595-0 |
| _version_ | 1818908787589775360 |
|---|---|
| author | Pouya Safarzadeh Kozani Pooria Safarzadeh Kozani Fatemeh Rahbarizadeh |
| author_facet | Pouya Safarzadeh Kozani Pooria Safarzadeh Kozani Fatemeh Rahbarizadeh |
| author_sort | Pouya Safarzadeh Kozani |
| collection | DOAJ |
| description | Abstract Chimeric antigen receptor T-cell (CAR-T) therapy has been prosperous in the treatment of patients with various types of relapsed/refractory (R/R) B-cell malignancies including diffuse large B-cell lymphoma (DLBCL), B-cell acute lymphoblastic leukemia (B-ALL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and multiple myeloma (MM). However, this type of therapy has faced serious hindrances in combating T-cell neoplasms. R/R T-cell malignancies are generally associated with poor clinical outcomes, and the available effective treatment approaches are very limited. CAR-T therapy of T-cell malignancies has unique impediments in comparison with that of B-cell malignancies. Fratricide, T-cell aplasia, and product contamination with malignant T cells when producing autologous CAR-Ts are the most important challenges of CAR-T therapy in T-cell malignancies necessitating in-depth investigations. Herein, we highlight the preclinical and clinical efforts made for addressing these drawbacks and also review additional potent stratagems that could improve CAR-T therapy in T-cell malignancies. |
| first_indexed | 2024-12-19T22:16:34Z |
| format | Article |
| id | doaj.art-f143fe4da184406cb8c18faa2ee251bc |
| institution | Directory Open Access Journal |
| issn | 1757-6512 |
| language | English |
| last_indexed | 2024-12-19T22:16:34Z |
| publishDate | 2021-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj.art-f143fe4da184406cb8c18faa2ee251bc2022-12-21T20:03:46ZengBMCStem Cell Research & Therapy1757-65122021-10-0112111710.1186/s13287-021-02595-0CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?Pouya Safarzadeh Kozani0Pooria Safarzadeh Kozani1Fatemeh Rahbarizadeh2Department of Medical Biotechnology, Faculty of Paramedicine, Guilan University of Medical SciencesDepartment of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares UniversityDepartment of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares UniversityAbstract Chimeric antigen receptor T-cell (CAR-T) therapy has been prosperous in the treatment of patients with various types of relapsed/refractory (R/R) B-cell malignancies including diffuse large B-cell lymphoma (DLBCL), B-cell acute lymphoblastic leukemia (B-ALL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and multiple myeloma (MM). However, this type of therapy has faced serious hindrances in combating T-cell neoplasms. R/R T-cell malignancies are generally associated with poor clinical outcomes, and the available effective treatment approaches are very limited. CAR-T therapy of T-cell malignancies has unique impediments in comparison with that of B-cell malignancies. Fratricide, T-cell aplasia, and product contamination with malignant T cells when producing autologous CAR-Ts are the most important challenges of CAR-T therapy in T-cell malignancies necessitating in-depth investigations. Herein, we highlight the preclinical and clinical efforts made for addressing these drawbacks and also review additional potent stratagems that could improve CAR-T therapy in T-cell malignancies.https://doi.org/10.1186/s13287-021-02595-0Chimeric antigen receptorT-cell malignanciesFratricideT-cell aplasiaNatural killer cellsCancer immunotherapy |
| spellingShingle | Pouya Safarzadeh Kozani Pooria Safarzadeh Kozani Fatemeh Rahbarizadeh CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit? Stem Cell Research & Therapy Chimeric antigen receptor T-cell malignancies Fratricide T-cell aplasia Natural killer cells Cancer immunotherapy |
| title | CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit? |
| title_full | CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit? |
| title_fullStr | CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit? |
| title_full_unstemmed | CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit? |
| title_short | CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit? |
| title_sort | car t cell therapy in t cell malignancies is success a low hanging fruit |
| topic | Chimeric antigen receptor T-cell malignancies Fratricide T-cell aplasia Natural killer cells Cancer immunotherapy |
| url | https://doi.org/10.1186/s13287-021-02595-0 |
| work_keys_str_mv | AT pouyasafarzadehkozani cartcelltherapyintcellmalignanciesissuccessalowhangingfruit AT pooriasafarzadehkozani cartcelltherapyintcellmalignanciesissuccessalowhangingfruit AT fatemehrahbarizadeh cartcelltherapyintcellmalignanciesissuccessalowhangingfruit |